PIK3CD and non-Hodgkin lymphoma: Copanlisib (BAY 80-6946) and Duvelisib (IPI-145) are newly approved PI3K inhibitors that offer objective, although relatively short-lasting, responses in patients with heavily pre-treated FL and other NHL, and more such targeted agents may be approved soon [307, 317–320] (Tables 2 and 3).